Covestor’s TG Therapeutics TGTX Stock Holding History

Covestor’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$124K	Sell	2,258 -123	-5%	-$5.03K	0.07%	265
2026 Q1	$79K	Buy	2,381 +571	+32%	+$17K	0.05%	404
2025 Q4	$54K	Buy	1,810 +1,537	+563%	+$50.2K	0.03%	883
2025 Q3	$10K	Hold	273	–	–	0.01%	1616
2025 Q2	$10K	Buy	273 +265	+3,313%	+$9.87K	0.01%	1611
2025 Q1	$0	Hold	8	–	–	﹤0.01%	2721
2024 Q4	$0	Hold	8	–	–	﹤0.01%	2735
2024 Q3	$0	Sell	8 -3	-27%	-$66	﹤0.01%	2760
2024 Q2	$0	Hold	11	–	–	﹤0.01%	2748
2024 Q1	$0	Sell	11 -4	-27%	-$64	﹤0.01%	2730
2023 Q4	$0	Buy	15 +7	+88%	+$81	﹤0.01%	2707
2023 Q3	$0	Sell	8 -1	-11%	-$14	﹤0.01%	2704
2023 Q2	$0	Sell	9 -3	-25%	-$77	﹤0.01%	2642
2023 Q1	$0	Buy	+12	New	+$182	﹤0.01%	2581
2022 Q1	–	Sell	-3	Closed	–	–	2442
2021 Q4	$0	Buy	+3	New	+$78	﹤0.01%	2299

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Covestor's TGTX Position: Q2 2026 in Review

Covestor reduced its TG Therapeutics (TGTX) stake by 5.2% in Q2 2026, selling an estimated $5.03K and leaving 2,258 shares worth $124K. The position accounts for 0.07% of the portfolio, ranked #265.

Covestor first reported a position in TGTX in Q4 2021 and has held it in 15 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Covestor held 2,258 shares of TG Therapeutics worth $124K as of Q2 2026.
Covestor sold 123 TG Therapeutics shares in Q2 2026, an estimated $5.03K.
TG Therapeutics made up 0.07% of Covestor's portfolio in Q2 2026, its #265 holding.
Covestor first reported a position in TG Therapeutics in Q4 2021 and has held it in 15 quarters since.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.